Matches in SemOpenAlex for { <https://semopenalex.org/work/W81857156> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W81857156 endingPage "5010" @default.
- W81857156 startingPage "5010" @default.
- W81857156 abstract "5010 Background: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor of VEGFRs and PDGFRs, approved multinationally for advanced RCC. The primary aim of this international, open-label trial was to provide sunitinib to mRCC pts who failed =1 prior systemic therapy and were ineligible for other sunitinib trials or had no access to sunitinib before regulatory approval in their country. Methods: Eligibility criteria were minimized to broaden the enrolment population. Pts who were 18 yrs of age or older with histologically-confirmed mRCC received oral sunitinib 50 mg/day in 6-wk cycles (4 wks on Tx, 2 wks off). Physical exam, safety and concomitant meds were assessed every 4 wks. Results: As of Sept 1, 2006, 4,000 pts were enrolled from 181 sites in 36 countries; 2,158 pts (median age, 59 [19- 85]; male/female, 74%/26%) were included in this analysis. Baseline demographics included 106 pts (5%) with non-clear cell histology; 173 pts (8%) with brain mets; 158 pts (7%) with prior antiangiogenic Tx; and 288 pts (13%) with ECOG PS =2. Median Tx duration was 128 days (range 1- 2444) with interruptions in 17% of pts and dose reductions in 30%; 672 pts (31%) discontinued, of which 80 pts (12%) discontinued due to AEs. The median Tx duration was similar to the overall population regardless of age or site of metastatic disease at baseline (brain, bone, lung, liver, lymph nodes or other), but was longer in pts with ECOG PS 0/1 (154 days, range 1–2,444) than with ECOG PS =2 (83 days, range 1–449). The most common treatment-related AEs were diarrhea (39% any grade, 3% grade 3/4), fatigue (35%, 7%) and nausea (33%, 2%), the incidences of which were similar in pts regardless of age or site of baseline metastatic disease; overall, they occurred more frequently in pts with ECOG PS 0/1 vs. ECOG PS =2 (42% vs. 21%, 38% vs. 23%; and 34% vs. 25%, respectively), but differences in grade 3/4 severity were not observed. Median overall survival has not been reached; 19% of pts have died, the lowest incidence among pts with ECOG PS 0/1 (15%) and highest in pts with ECOG PS =2 (43%) and brain mets (34%). Conclusions: Preliminary observations suggest that sunitinib is associated with acceptable tolerability in an expanded access trial regardless of age or site of baseline metastatic disease. [Table: see text]" @default.
- W81857156 created "2016-06-24" @default.
- W81857156 creator A5018910230 @default.
- W81857156 creator A5021550191 @default.
- W81857156 creator A5024147987 @default.
- W81857156 creator A5025529463 @default.
- W81857156 creator A5039344852 @default.
- W81857156 creator A5049048398 @default.
- W81857156 creator A5059690857 @default.
- W81857156 creator A5061327271 @default.
- W81857156 creator A5063293745 @default.
- W81857156 creator A5082466279 @default.
- W81857156 date "2007-06-20" @default.
- W81857156 modified "2023-10-14" @default.
- W81857156 title "Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis" @default.
- W81857156 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.5010" @default.
- W81857156 hasPublicationYear "2007" @default.
- W81857156 type Work @default.
- W81857156 sameAs 81857156 @default.
- W81857156 citedByCount "42" @default.
- W81857156 countsByYear W818571562013 @default.
- W81857156 countsByYear W818571562014 @default.
- W81857156 countsByYear W818571562021 @default.
- W81857156 crossrefType "journal-article" @default.
- W81857156 hasAuthorship W81857156A5018910230 @default.
- W81857156 hasAuthorship W81857156A5021550191 @default.
- W81857156 hasAuthorship W81857156A5024147987 @default.
- W81857156 hasAuthorship W81857156A5025529463 @default.
- W81857156 hasAuthorship W81857156A5039344852 @default.
- W81857156 hasAuthorship W81857156A5049048398 @default.
- W81857156 hasAuthorship W81857156A5059690857 @default.
- W81857156 hasAuthorship W81857156A5061327271 @default.
- W81857156 hasAuthorship W81857156A5063293745 @default.
- W81857156 hasAuthorship W81857156A5082466279 @default.
- W81857156 hasConcept C121608353 @default.
- W81857156 hasConcept C126322002 @default.
- W81857156 hasConcept C126894567 @default.
- W81857156 hasConcept C141071460 @default.
- W81857156 hasConcept C143998085 @default.
- W81857156 hasConcept C2775832928 @default.
- W81857156 hasConcept C2777472916 @default.
- W81857156 hasConcept C2778820342 @default.
- W81857156 hasConcept C2779384505 @default.
- W81857156 hasConcept C2779490328 @default.
- W81857156 hasConcept C2908647359 @default.
- W81857156 hasConcept C71924100 @default.
- W81857156 hasConcept C90924648 @default.
- W81857156 hasConcept C99454951 @default.
- W81857156 hasConceptScore W81857156C121608353 @default.
- W81857156 hasConceptScore W81857156C126322002 @default.
- W81857156 hasConceptScore W81857156C126894567 @default.
- W81857156 hasConceptScore W81857156C141071460 @default.
- W81857156 hasConceptScore W81857156C143998085 @default.
- W81857156 hasConceptScore W81857156C2775832928 @default.
- W81857156 hasConceptScore W81857156C2777472916 @default.
- W81857156 hasConceptScore W81857156C2778820342 @default.
- W81857156 hasConceptScore W81857156C2779384505 @default.
- W81857156 hasConceptScore W81857156C2779490328 @default.
- W81857156 hasConceptScore W81857156C2908647359 @default.
- W81857156 hasConceptScore W81857156C71924100 @default.
- W81857156 hasConceptScore W81857156C90924648 @default.
- W81857156 hasConceptScore W81857156C99454951 @default.
- W81857156 hasIssue "18_suppl" @default.
- W81857156 hasLocation W818571561 @default.
- W81857156 hasOpenAccess W81857156 @default.
- W81857156 hasPrimaryLocation W818571561 @default.
- W81857156 hasRelatedWork W1748917316 @default.
- W81857156 hasRelatedWork W1931475962 @default.
- W81857156 hasRelatedWork W2011407321 @default.
- W81857156 hasRelatedWork W2027281830 @default.
- W81857156 hasRelatedWork W2046457441 @default.
- W81857156 hasRelatedWork W2075668427 @default.
- W81857156 hasRelatedWork W2106797482 @default.
- W81857156 hasRelatedWork W2106908546 @default.
- W81857156 hasRelatedWork W2377837277 @default.
- W81857156 hasRelatedWork W3133628686 @default.
- W81857156 hasVolume "25" @default.
- W81857156 isParatext "false" @default.
- W81857156 isRetracted "false" @default.
- W81857156 magId "81857156" @default.
- W81857156 workType "article" @default.